Mr. Sukhtian has served as a member of our Board since September 2017. Mr. Sukhtian has served as a Director of GMS Tenshi Holdings Pte. Limited since 2011, and an Executive Director of GMS Holdings, a diversified investment company, since 2008. In addition to managing operations of GMS Holdings,Mr. Sukhtian oversees a number of investments within the GMS Holdings portfolio and serves as a director of GMS Holdings’ board of directors. From 2008 to 2011, Mr. Sukhtian served as Executive Director of Munir Sukhtian International. From 2010 to 2011, he served as Managing Director of Agri Sciences Ltd., an agrochemicals manufacturing business based in Turkey. Mr. Sukhtian has served as a member of the board of directors of Expert Petroleum, an oilfield services company based in Romania, since 2008, Agri Sciences since 2010, MS Pharma, a leading MENA based branded pharmaceutical generics company, since 2011 and Stelis Biopharma Private Limited, a biotherapeutic and biosimilar developer and manufacturer based in India, since 2015. Mr. Sukhtian previously served as a member of the board ofdirectors of Alvogen, a multinational generics pharmaceutical company based in the United States, from 2008 to 2014 and Waterloo Industries, Inc., a manufacturer of tool storage based in the United States, from 2015 to 2017. Prior to joining GMS Holdings, Mr. Sukhtian worked at JP Morgan, in New York, where he worked primarily on mergers and acquisitions, debt and equity transactions serving clients in the industrials and transportation industries.
Mr. Sukhtian received an M.B.A. from Columbia Business School and a B.S. in International Economics from Georgetown University’s School of Foreign Service. Mr. Sukhtian was appointed to fill a vacancy on the Board, and was designated for such vacancy by GMS Tenshi Holdings Pte. Limited pursuant to the Investor Rights Agreement by and between the Company and GMS Tenshi Holdings Pte. Limited dated September 11, 2017.
How do I contact Ghiath M. Sukhtian?
Has Ghiath M. Sukhtian been buying or selling shares of Outlook Therapeutics?
Ghiath M. Sukhtian has not been actively trading shares of Outlook Therapeutics in the last ninety days. Most recently, on Monday, November 29th, Ghiath M. Sukhtian bought 800,000 shares of Outlook Therapeutics stock. The stock was acquired at an average cost of $25.00 per share, with a total value of $20,000,000.00. Learn More on Ghiath M. Sukhtian's trading history.
Who are Outlook Therapeutics' active insiders?
Are insiders buying or selling shares of Outlook Therapeutics?
In the last year, Outlook Therapeutics insiders bought shares 1 times. They purchased a total of 1,882 shares worth more than $22,245.24. The most recent insider tranaction occured on March, 28th when Director Yezan Munther Haddadin bought 1,882 shares worth more than $22,245.24. Insiders at Outlook Therapeutics own 5.3% of the company.
Learn More about insider trades at Outlook Therapeutics. Information on this page was last updated on 3/28/2024.
